The effect of CD3-specific monoclonal antibody on treating experimental autoimmune myasthenia gravis.
CD3-specific monoclonal antibody was the first one used for clinical practice in field of transplantation. Recently, renewed interests have elicited in its capacity to prevent autoimmune diabetes by inducing immune tolerance. In this study, we tested whether this antibody can also be used to treat another kind of autoimmune disease myasthenia gravis (MG) and explored the possible mechanisms. MG is caused by an autoimmune damage mediated by antibody- and complement-mediated destruction of AChR at the neuromuscular junction. We found that administration of CD3-specific antibody (Fab)2 to an animal model with experimental autoimmune myasthenia gravis (EAMG) (B6 mice received 3 times of AChR/CFA immunization) could not significantly improve the clinical signs and clinical score. When the possible mechanisms were tested, we found that CD3 antibody treatment slightly down-regulated the T-cell response to AChR, modestly up-regulating the muscle strength. And no significant difference in the titers of IgG2b was found between CD3 antibody treated and control groups. These data indicated that CD3-specific antibody was not suitable for treating MG, an antibody- and complement- mediated autoimmune disease, after this disease has been established. The role of CD3-specific antibody in treating this kind of disease remains to be determined.
Xu
Ruo Nan
RN
Institute of Basic Medical Science, Academy of Military Medical Science, Beijing 100850, China.
Wang
Jia Nan
JN
Chen
Guo Jiang
GJ
Han
Gen Cheng
GC
Wang
Ren Xi
RX
Shen
Bei Fen
BF
Li
Yan
Y
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000627:therapeutic use*; D017252:CD3 Complex / Q000276:immunology*; D049109:Cell Proliferation / Q000187:drug effects; D004576:Electromyography; D005260:Female; D008214:Lymphocytes / Q000166:cytology / Q000187:drug effects; D051379:Mice; D020720:Myasthenia Gravis, Autoimmune, Experimental / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology* / Q000517:prevention & control; D013154:Spleen / Q000166:cytology / Q000187:drug effects
D000911:Antibodies, Monoclonal; D017252:CD3 Complex